Pathways to tamoxifen resistance

Cancer Letters

Volumn 256, Issue 1, 2007, Pages 1-24

  Riggins, Rebecca B ^a   Schrecengost, Randy S ^b   Guerrero, Michael S ^b   Bouton, Amy H ^b  

^a GEORGETOWN UNIVERSITY   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Antiestrogen; Aromatase inhibitor; Estrogen receptor; Fulvestrant; Tamoxifen

Indexed keywords

21 (4 DIETHYLAMINOMETHYL 2 METHOXYPHENOXY) 7ALPHA METHYL 19 NORPREGNA 1,3,5(10) TRIEN 3 OL; 5 AZA 2' DEOXYCYTIDINE; ANASTROZOLE; ANTIESTROGEN; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; AZD 0530; CELLULAR APOPTOSIS SUSCEPTIBILITY PROTEIN; DIARYLPROPIONITRILE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; EVEROLIMUS; EXEMESTANE; FULVESTRANT; GEFITINIB; GROWTH FACTOR RECEPTOR; HORMONE; LAPATINIB; LETROZOLE; MIFEPRISTONE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR DOWNREGULATOR; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TEMSIROLIMUS; TIPIFARNIB; TRASTUZUMAB; TRICHOSTATIN A; UNCLASSIFIED DRUG;

APOPTOSIS; BREAST CANCER; CANCER CHEMOTHERAPY; CELL CYCLE ARREST; CELL CYCLE REGULATION; CELL DIFFERENTIATION; CELL INVASION; CELL MOTILITY; CELL PROLIFERATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DOWN REGULATION; DRUG ANTAGONISM; DRUG INHIBITION; DRUG MECHANISM; ENDOMETRIUM CANCER; GENE EXPRESSION; HUMAN; LACTATION; METASTASIS; MONOTHERAPY; MUTATION; NONHUMAN; ONCOGENE SRC; PHENOTYPE; PREDICTION; PREGNANCY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SHORT SURVEY; UNSPECIFIED SIDE EFFECT;

BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; RECEPTORS, ESTROGEN; SIGNAL TRANSDUCTION; TAMOXIFEN;

EID: 34548237309     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2007.03.016     Document Type: Review

References (216)

1. Ascenzi P., Bocedi A., and Marino M. Structure-function relationship of estrogen receptor alpha and beta: impact on human health. Mol. Aspects Med. 27 (2006) 299-402
2. Anderson E., and Clarke R.B. Steroid receptors and cell cycle in normal mammary epithelium. J. Mammary Gland Biol. Neoplasia 9 (2004) 3-13
3. Speirs V., Skliris G.P., Burdall S.E., and Carder P.J. Distinct expression patterns of ER alpha and ER beta in normal human mammary gland. J. Clin. Pathol. 55 (2002) 371-374
4. Forster C., Makela S., Warri A., Kietz S., Becker D., Hultenby K., et al. Involvement of estrogen receptor beta in terminal differentiation of mammary gland epithelium. Proc. Natl. Acad. Sci. USA 99 (2002) 15578-15583
5. Saji S., Hirose M., and Toi M. Clinical significance of estrogen receptor beta in breast cancer. Cancer Chemother. Pharmacol. 56 Suppl. 1 (2005) 21-26
6. Murphy L.C., and Watson P.H. Is oestrogen receptor-beta a predictor of endocrine therapy responsiveness in human breast cancer?. Endocr. Relat. Cancer 13 (2006) 327-334
7. Matthews J., Wihlen B., Tujague M., Wan J., Strom A., and Gustafsson J.A. Estrogen receptor (ER) beta modulates ER alpha-mediated transcriptional activation by altering the recruitment of c-fos and c-jun to estrogen-responsive promoters. Mol. Endocrinol. 20 (2006) 534-543
8. Helguero L.A., Faulds M.H., Gustafsson J.A., and Haldosen L.A. Estrogen receptors alpha (ER alpha) and beta (ER beta) differentially regulate proliferation and apoptosis of the normal murine mammary epithelial cell line HC11. Oncogene 24 (2005) 6605-6616
9. Stossi F., Barnett D.H., Frasor J., Komm B., Lyttle C.R., and Katzenellenbogen B.S. Transcriptional profiling of estrogen-regulated gene expression via estrogen receptor (ER) alpha or ER beta in human osteosarcoma cells: distinct and common target genes for these receptors. Endocrinology 145 (2004) 3473-3486
10. Chang E.C., Frasor J., Komm B., and Katzenellenbogen B.S. Impact of estrogen receptor beta on gene networks regulated by estrogen receptor alpha in breast cancer cells. Endocrinology 147 (2006) 4831-4842
11. Lewis J.S., and Jordan V.C. Selective estrogen receptor modulators (SERMs): mechanisms of anticarcinogenesis and drug resistance. Mutat. Res. 591 (2005) 247-263
12. Fisher B., Costantino J.P., Wickerham D.L., Redmond C.K., Kavanah M., Cronin W.M., et al. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl. Cancer Inst. 90 (1998) 1371-1388
13. Veeneman G.H. Non-steroidal subtype selective estrogens. Curr. Med. Chem. 12 (2005) 1077-1136
14. Escande A., Pillon A., Servant N., Cravedi J.P., Larrea F., Muhn P., et al. Evaluation of ligand selectivity using reporter cell lines stably expressing estrogen receptor alpha or beta. Biochem. Pharmacol. 71 (2006) 1459-1469
15. Blizzard T.A., Gude C., Morgan II J.D., Chan W., Birzin E.T., Mojena M., et al. Androstenediol analogs as ER-beta-selective SERMs. Bioorg. Med. Chem. Lett. 16 (2006) 834-838
16. Buzdar A.U. TAS-108: a novel steroidal antiestrogen. Clin. Cancer Res. 11 (2005) 906S-908S
17. Howell A. Pure oestrogen antagonists for the treatment of advanced breast cancer. Endocr. Relat. Cancer 13 (2006) 689-706
18. Osborne C.K., Wakeling A., and Nicholson R.I. Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action. Br. J. Cancer 90 Suppl. 1 (2004) S2-S6
19. Brueggemeier R.W. Update on the use of aromatase inhibitors in breast cancer. Expert Opin. Pharmacother. 7 (2006) 1919-1930
20. Riggins R.B., Bouton A.H., Liu M.C., and Clarke R. Antiestrogens, aromatase inhibitors, and apoptosis in breast cancer. Vitam. Horm. 71 (2005) 201-237
21. Chen S., Masri S., Wang X., Phung S., Yuan Y.C., and Wu X. What do we know about the mechanisms of aromatase inhibitor resistance?. J. Steroid Biochem. Mol. Biol. 102 (2006) 232-240
22. Carroll J.S., Prall O.W., Musgrove E.A., and Sutherland R.L. A pure estrogen antagonist inhibits cyclin E-CDK2 activity in MCF-7 breast cancer cells and induces accumulation of p130-E2F4 complexes characteristic of quiescence. J. Biol. Chem. 275 (2000) 38221-38229
23. Doisneau-Sixou S.F., Cestac P., Faye J.C., Favre G., and Sutherland R.L. Additive effects of tamoxifen and the farnesyl transferase inhibitor FTI-277 on inhibition of MCF-7 breast cancer cell-cycle progression. Int. J. Cancer 106 (2003) 789-798
24. Thiantanawat A., Long B.J., and Brodie A.M. Signaling pathways of apoptosis activated by aromatase inhibitors and antiestrogens. Cancer Res. 63 (2003) 8037-8050
25. Bouker K.B., Skaar T.C., Fernandez D.R., O'Brien K.A., Riggins R.B., Cao D., et al. Interferon regulatory factor-1 mediates the proapoptotic but not cell cycle arrest effects of the steroidal antiestrogen ICI 182,780 (faslodex, fulvestrant). Cancer Res. 64 (2004) 4030-4039
26. Doisneau-Sixou S.F., Sergio C.M., Carroll J.S., Hui R., Musgrove E.A., and Sutherland R.L. Estrogen and antiestrogen regulation of cell cycle progression in breast cancer cells. Endocr. Relat. Cancer 10 (2003) 179-186
27. Arpino G., Green S.J., Allred D.C., Lew D., Martino S., Osborne C.K., et al. HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group Study. Clin. Cancer Res. 10 (2004) 5670-5676
28. Gee J.M., Robertson J.F., Gutteridge E., Ellis I.O., Pinder S.E., Rubini M., et al. Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer. Endocr. Relat. Cancer 12 Suppl. 1 (2005) S99-S111
29. Dowsett M., Johnston S., Martin L.A., Salter J., Hills M., Detre S., et al. Growth factor signalling and response to endocrine therapy: The Royal Marsden Experience. Endocr. Relat. Cancer 12 Suppl. 1 (2005) S113-S117
30. Gutierrez M.C., Detre S., Johnston S., Mohsin S.K., Shou J., Allred D.C., et al. Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. J. Clin. Oncol. 23 (2005) 2469-2476
31. Kirkegaard T., Witton C.J., McGlynn L.M., Tovey S.M., Dunne B., Lyon A., et al. AKT activation predicts outcome in breast cancer patients treated with tamoxifen. J. Pathol. 207 (2005) 139-146
32. Holm C., Rayala S., Jirstrom K., Stal O., Kumar R., and Landberg G. Association between Pak1 expression and subcellular localization and tamoxifen resistance in breast cancer patients. J. Natl. Cancer Inst. 98 (2006) 671-680
33. Cas protein and primary breast cancer: prognosis and response to tamoxifen treatment. J. Natl. Cancer Inst. 92 (2000) 120-127
34. Osborne C.K., Bardou V., Hopp T.A., Chamness G.C., Hilsenbeck S.G., Fuqua S.A., et al. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J. Natl. Cancer Inst. 95 (2003) 353-361
35. Sarwar N., Kim J.S., Jiang J., Peston D., Sinnett H.D., Madden P., et al. Phosphorylation of ER alpha at serine 118 in primary breast cancer and in tamoxifen-resistant tumours is indicative of a complex role for ER alpha phosphorylation in breast cancer progression. Endocr. Relat. Cancer 13 (2006) 851-861
36. Cannings E., Kirkegaard T., Tovey S.M., Dunne B., Cooke T.G., and Bartlett J.M. Bad expression predicts outcome in patients treated with tamoxifen. Breast Cancer Res. Treat. 102 (2007) 173-179
37. Linke S.P., Bremer T.M., Herold C.D., Sauter G., and Diamond C. A multimarker model to predict outcome in tamoxifen-treated breast cancer patients. Clin. Cancer Res. 12 (2006) 1175-1183
38. Planas-Silva M.D., Bruggeman R.D., Grenko R.T., and Smith J.S. Overexpression of c-Myc and Bcl-2 during progression and distant metastasis of hormone-treated breast cancer. Exp. Mol. Pathol. 82 (2007) 85-90
39. Rahko E., Blanco G., Bloigu R., Soini Y., Talvensaari-Mattila A., and Jukkola A. Adverse outcome and resistance to adjuvant antiestrogen therapy in node-positive postmenopausal breast cancer patients-the role of p53. Breast 15 (2006) 69-75
40. Kuiper G.G., Enmark E., Pelto-Huikko M., Nilsson S., and Gustafsson J.A. Cloning of a novel receptor expressed in rat prostate and ovary. Proc. Natl. Acad. Sci. USA 93 (1996) 5925-5930
41. McDonnell D.P. The molecular determinants of estrogen receptor pharmacology. Maturitas 48 Suppl. 1 (2004) S7-S12
42. Paech K., Webb P., Kuiper G.G., Nilsson S., Gustafsson J., Kushner P.J., et al. Differential ligand activation of estrogen receptors ER alpha and ER beta at AP1 sites. Science 277 (1997) 1508-1510
43. Zou A., Marschke K.B., Arnold K.E., Berger E.M., Fitzgerald P., Mais D.E., et al. Estrogen receptor beta activates the human retinoic acid receptor alpha-1 promoter in response to tamoxifen and other estrogen receptor antagonists, but not in response to estrogen. Mol. Endocrinol. 13 (1999) 418-430
44. Smith C.L., and O'Malley B.W. Coregulator function: a key to understanding tissue specificity of selective receptor modulators. Endocr. Rev. 25 (2004) 45-71
45. Hall J.M., and McDonnell D.P. Coregulators in nuclear estrogen receptor action: from concept to therapeutic targeting. Mol. Interv. 5 (2005) 343-357
46. Kumar R., Gururaj A.E., Vadlamudi R.K., and Rayala S.K. The clinical relevance of steroid hormone receptor corepressors. Clin. Cancer Res. 11 (2005) 2822-2831
47. Girault I., Bieche I., and Lidereau R. Role of estrogen receptor alpha transcriptional coregulators in tamoxifen resistance in breast cancer. Maturitas 54 (2006) 342-351
48. Clarke R., Leonessa F., Welch J.N., and Skaar T.C. Cellular and molecular pharmacology of antiestrogen action and resistance. Pharmacol. Rev. 53 (2001) 25-71
49. Honig S.F. Treatment of metastatic disease: hormonal therapy and chemotherapy. In: Harris J.R., Lippman M.E., Morrow M., and Helman S. (Eds). Diseases of the Breast (1996), Lippincott-Raven, Philadelphia 669-734
50. Ottaviano Y.L., Issa J.P., Parl F.F., Smith H.S., Baylin S.B., and Davidson N.E. Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells. Cancer Res. 54 (1994) 2552-2555
51. Roodi N., Bailey L.R., Kao W.Y., Verrier C.S., Yee C.J., Dupont W.D., et al. Estrogen receptor gene analysis in estrogen receptor-positive and receptor-negative primary breast cancer. J. Natl. Cancer Inst. 87 (1995) 446-451
52. Sharma D., Saxena N.K., Davidson N.E., and Vertino P.M. Restoration of tamoxifen sensitivity in estrogen receptor-negative breast cancer cells: tamoxifen-bound reactivated ER recruits distinctive corepressor complexes. Cancer Res. 66 (2006) 6370-6378
53. Giacinti L., Claudio P.P., Lopez M., and Giordano A. Epigenetic information and estrogen receptor alpha expression in breast cancer. Oncologist 11 (2006) 1-8
54. Garcia M., Derocq D., Freiss G., and Rochefort H. Activation of estrogen receptor transfected into a receptor-negative breast cancer cell line decreases the metastatic and invasive potential of the cells. Proc. Natl. Acad. Sci. USA 89 (1992) 11538-11542
55. Johnston S.R., Saccani-Jotti G., Smith I.E., Salter J., Newby J., Coppen M., et al. Changes in estrogen receptor, progesterone receptor, and PS2 expression in tamoxifen-resistant human breast cancer. Cancer Res. 55 (1995) 3331-3338
56. Encarnacion C.A., Ciocca D.R., McGuire W.L., Clark G.M., Fuqua S.A., and Osborne C.K. Measurement of steroid hormone receptors in breast cancer patients on tamoxifen. Breast Cancer Res. Treat. 26 (1993) 237-246
57. Clarke R., Skaar T.C., Bouker K.B., Davis N., Lee Y.R., Welch J.N., et al. Molecular and pharmacological aspects of antiestrogen resistance. J. Steroid Biochem. Mol. Biol. 76 (2001) 71-84
58. van den Berg H.W., Lynch M., Martin J., Nelson J., Dickson G.R., and Crockard A.D. Characterisation of a tamoxifen-resistant variant of the ZR-75-1 human breast cancer cell line (ZR-75-9a1) and ability of the resistant phenotype. Br. J. Cancer 59 (1989) 522-526
59. Sommer A., Hoffmann J., Lichtner R.B., Schneider M.R., and Parczyk K. Studies on the development of resistance to the pure antiestrogen faslodex in three human breast cancer cell lines. J. Steroid Biochem. Mol. Biol. 85 (2003) 33-47
60. Fan M., Yan P.S., Hartman-Frey C., Chen L., Paik H., Oyer S.L., et al. Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant. Cancer Res. 66 (2006) 11954-11966
61. Larsen S.S., Madsen M.W., Jensen B.L., and Lykkesfeldt A.E. Resistance of human breast-cancer cells to the pure steroidal anti-estrogen ICI 182,780 is not associated with a general loss of estrogen-receptor expression or lack of estrogen responsiveness. Int. J. Cancer 72 (1997) 1129-1136
62. Jensen B.L., Skouv J., Lundholt B.K., and Lykkesfeldt A.E. Differential regulation of specific genes in MCF-7 and the ICI 182780-resistant cell line MCF-7/182R-6. Br. J. Cancer 79 (1999) 386-392
63. Brunner N., Boysen B., Jirus S., Skaar T.C., Holst-Hansen C., Lippman J., et al. MCF7/LCC9: an antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182,780 confers an early cross-resistance to the nonsteroidal antiestrogen tamoxifen. Cancer Res. 57 (1997) 3486-3493
64. Brunner N., Boulay V., Fojo A., Freter C.E., Lippman M.E., and Clarke R. Acquisition of hormone-independent growth in MCF-7 cells is accompanied by increased expression of estrogen-regulated genes but without detectable DNA amplifications. Cancer Res. 53 (1993) 283-290
65. Kuske B., Naughton C., Moore K., Macleod K.G., Miller W.R., Clarke R., et al. Endocrine therapy resistance can be associated with high estrogen receptor α (ERα) expression and reduced ERα phosphorylation in breast cancer models. Endocr. Relat. Cancer 13 (2006) 1121-1133
66. Riggins R.B., Zwart A., Nehra R., and Clarke R. The nuclear factor kappa B inhibitor parthenolide restores ICI 182,780 (faslodex; fulvestrant)-induced apoptosis in antiestrogen-resistant breast cancer cells. Mol. Cancer Ther. 4 (2005) 33-41
67. Howell A. Fulvestrant ('faslodex'): current and future role in breast cancer management. Crit. Rev. Oncol. Hematol. 57 (2006) 265-273
68. CO cells, genetically unstable and containing estrogen receptor mutations, are a model for the progression of breast cancers to hormone resistance. Cancer Res. 50 (1990) 6208-6217
69. Graham II M.L., Smith J.A., Jewett P.B., and Horwitz K.B. Heterogeneity of progesterone receptor content and remodeling by tamoxifen characterize subpopulations of cultured human breast cancer cells: analysis by quantitative dual parameter flow cytometry. Cancer Res. 52 (1992) 593-602
70. Herynk M.H., and Fuqua S.A. Estrogen receptor mutations in human disease. Endocr. Rev. 25 (2004) 869-898
71. Pink J.J., Wu S.Q., Wolf D.M., Bilimoria M.M., and Jordan V.C. A novel 80 kDa human estrogen receptor containing a duplication of exons 6 and 7. Nucleic Acids Res. 24 (1996) 962-969
72. Karnik P.S., Kulkarni S., Liu X.P., Budd G.T., and Bukowski R.M. Estrogen receptor mutations in tamoxifen-resistant breast cancer. Cancer Res. 54 (1994) 349-353
73. Zhang Q.X., Borg A., Wolf D.M., Oesterreich S., and Fuqua S.A. An estrogen receptor mutant with strong hormone-independent activity from a metastatic breast cancer. Cancer Res. 57 (1997) 1244-1249
74. Fuqua S.A., Wiltschke C., Zhang Q.X., Borg A., Castles C.G., Friedrichs W.E., et al. A hypersensitive estrogen receptor-alpha mutation in premalignant breast lesions. Cancer Res. 60 (2000) 4026-4029
75. Zhang Z., Yamashita H., Toyama T., Omoto Y., Sugiura H., Hara Y., et al. Estrogen receptor alpha mutation (A-to-G transition at nucleotide 908) is not found in different types of breast lesions from Japanese women. Breast Cancer 10 (2003) 70-73
76. Navolanic P.M., Steelman L.S., and McCubrey J.A. EGFR family signaling and its association with breast cancer development and resistance to chemotherapy. Int. J. Oncol. 22 (2003) 237-252
77. Nicholson R.I., Hutcheson I.R., Knowlden J.M., Jones H.E., Harper M.E., Jordan N., et al. Nonendocrine pathways and endocrine resistance: observations with antiestrogens and signal transduction inhibitors in combination. Clin. Cancer Res. 10 (2004) 346S-354S
78. Nicholson R.I., Hutcheson I.R., Britton D., Knowlden J.M., Jones H.E., Harper M.E., et al. Growth factor signalling networks in breast cancer and resistance to endocrine agents: new therapeutic strategies. J. Steroid Biochem. Mol. Biol. 93 (2005) 257-262
79. Kurokawa H., Lenferink A.E., Simpson J.F., Pisacane P.I., Sliwkowski M.X., Forbes J.T., et al. Inhibition of HER2/neu (ErbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells. Cancer Res. 60 (2000) 5887-5894
80. Kurokawa H., and Arteaga C.L. Inhibition of ErbB receptor (HER) tyrosine kinases as a strategy to abrogate antiestrogen resistance in human breast cancer. Clin. Cancer Res. 7 (2001) 4436S-4442S discussion 4411S-4412S
81. Kurokawa H., and Arteaga C.L. ErbB (HER) receptors can abrogate antiestrogen action in human breast cancer by multiple signaling mechanisms. Clin. Cancer Res. 9 (2003) 511S-515S
82. McClelland R.A., Barrow D., Madden T.A., Dutkowski C.M., Pamment J., Knowlden J.M., et al. Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182,780 (faslodex). Endocrinology 142 (2001) 2776-2788
83. Knowlden J.M., Hutcheson I.R., Jones H.E., Madden T., Gee J.M., Harper M.E., et al. Elevated levels of epidermal growth factor receptor/c-ErbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology 144 (2003) 1032-1044
84. Hutcheson I.R., Knowlden J.M., Madden T.A., Barrow D., Gee J.M., Wakeling A.E., et al. Oestrogen receptor-mediated modulation of the EGFR/MAPK pathway in tamoxifen-resistant MCF-7 cells. Breast Cancer Res. Treat. 81 (2003) 81-93
85. Mendelsohn J., and Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene 19 (2000) 6550-6565
86. Yarden R.I., Wilson M.A., and Chrysogelos S.A. Estrogen suppression of EGFR expression in breast cancer cells: a possible mechanism to modulate growth. J. Cell. Biochem. 81 (2001) 232-246
87. Gee J.M., Harper M.E., Hutcheson I.R., Madden T.A., Barrow D., Knowlden J.M., et al. The antiepidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves antihormone response and prevents development of resistance in breast cancer in vitro. Endocrinology 144 (2003) 5105-5117
88. Okubo S., Kurebayashi J., Otsuki T., Yamamoto Y., Tanaka K., and Sonoo H. Additive antitumour effect of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa, ZD1839) and the antioestrogen fulvestrant (faslodex, ICI 182,780) in breast cancer cells. Br. J. Cancer 90 (2004) 236-244
89. Kumar R., Mandal M., Lipton A., Harvey H., and Thompson C.B. Overexpression of HER2 modulates Bcl-2, Bcl-xL, and tamoxifen-induced apoptosis in human MCF-7 breast cancer cells. Clin. Cancer Res. 2 (1996) 1215-1219
90. Shou J., Massarweh S., Osborne C.K., Wakeling A.E., Ali S., Weiss H., et al. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J. Natl. Cancer Inst. 96 (2004) 926-935
91. Lee H., and Bai W. Regulation of estrogen receptor nuclear export by ligand-induced and p38-mediated receptor phosphorylation. Mol. Cell. Biol. 22 (2002) 5835-5845
92. Riggins R.B., Thomas K.S., Ta H.Q., Wen J., Davis R.J., Schuh N.R., et al. Physical and functional interactions between Cas and c-Src induce tamoxifen resistance of breast cancer cells through pathways involving epidermal growth factor receptor and signal transducer and activator of transcription 5b. Cancer Res. 66 (2006) 7007-7015
93. Holloway J.N., Murthy S., and El-Ashry D. A cytoplasmic substrate of mitogen-activated protein kinase is responsible for estrogen receptor-alpha down-regulation in breast cancer cells: the role of nuclear factor-kappa B. Mol. Endocrinol. 18 (2004) 1396-1410
94. Schiff R., Massarweh S.A., Shou J., Bharwani L., Arpino G., Rimawi M., et al. Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators. Cancer Chemother. Pharmacol. 56 Suppl. 1 (2005) 10-20
95. Yang Z., Barnes C.J., and Kumar R. Human epidermal growth factor receptor 2 status modulates subcellular localization of and interaction with estrogen receptor alpha in breast cancer cells. Clin. Cancer Res. 10 (2004) 3621-3628
96. Massarweh S., Osborne C.K., Jiang S., Wakeling A.E., Rimawi M., Mohsin S.K., et al. Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer. Cancer Res. 66 (2006) 8266-8273
97. Brockdorff B.L., Heiberg I., and Lykkesfeldt A.E. Resistance to different antiestrogens is caused by different multi-factorial changes and is associated with reduced expression of IGF receptor 1 alpha. Endocr. Relat. Cancer 10 (2003) 579-590
98. Knowlden J.M., Hutcheson I.R., Barrow D., Gee J.M., and Nicholson R.I. Insulin-like growth factor-1 receptor signaling in tamoxifen-resistant breast cancer: a supporting role to the epidermal growth factor receptor. Endocrinology 146 (2005) 4609-4618
99. Santen R.J., Song R.X., Zhang Z., Kumar R., Jeng M.H., Masamura A., et al. Long-term estradiol deprivation in breast cancer cells up-regulates growth factor signaling and enhances estrogen sensitivity. Endocr. Relat. Cancer 12 Suppl. 1 (2005) S61-S73
100. Cesarone G., Garofalo C., Abrams M.T., Igoucheva O., Alexeev V., Yoon K., et al. RNAi-mediated silencing of insulin receptor substrate 1 (IRS-1) enhances tamoxifen-induced cell death in MCF-7 breast cancer cells. J. Cell Biochem. 98 (2006) 440-450
101. Dorssers L.C., van Agthoven T., Dekker A., van Agthoven T.L., and Kok E.M. Induction of antiestrogen resistance in human breast cancer cells by random insertional mutagenesis using defective retroviruses: identification of BCAR-1, a common integration site. Mol. Endocrinol. 7 (1993) 870-878
102. van Agthoven T., van Agthoven T.L., Dekker A., van der Spek P.J., Vreede L., and Dorssers L.C. Identification of BCAR3 by a random search for genes involved in antiestrogen resistance of human breast cancer cells. EMBO J. 17 (1998) 2799-2808
103. Bouton A.H., Riggins R.B., and Bruce-Staskal P.J. Functions of the adapter protein Cas: signal convergence and the determination of cellular responses. Oncogene 20 (2001) 6448-6458
104. Defilippi P., Di Stefano P., and Cabodi S. p130cas: a versatile scaffold in signaling networks. Trends Cell Biol. 16 (2006) 257-263
105. Cas, and antiestrogen resistance in breast cancer cells. J. Natl. Cancer Inst. 92 (2000) 112-120
106. Burnham M.R., Bruce-Staskal P.J., Harte M.T., Weidow C.L., Ma A., Weed S.A., et al. Regulation of c-Src activity and function by the adapter protein Cas. Mol. Cell. Biol. 20 (2000) 5865-5878
107. Riggins R.B., Quilliam L.A., and Bouton A.H. Synergistic promotion of c-Src activation and cell migration by Cas and AND-34/BCAR3. J. Biol. Chem. 278 (2003) 28264-28273
108. Cabodi S., Moro L., Baj G., Smeriglio M., Di Stefano P., Gippone S., et al. p130cas interacts with estrogen receptor alpha and modulates non-genomic estrogen signaling in breast cancer cells. J. Cell Sci. 117 (2004) 1603-1611
109. M.D. Planas-Silva, K.N. Hamilton, Targeting c-Src kinase enhances tamoxifen's inhibitory effect on cell growth by modulating expression of cell cycle and survival proteins, Cancer Chemother. Pharmacol., in press.
110. Cas/BCAR1, Fak and Src, via an adhesion-dependent pathway. Oncogene 25 (2006) 7597-7607
111. Ottenhoff-Kalff A.E., Rijksen G., van Beurden E.A., Hennipman A., Michels A.A., and Staal G.E. Characterization of protein tyrosine kinases from human breast cancer: Involvement of the c-Src oncogene product. Cancer Res. 52 (1992) 4773-4778
112. Verbeek B.S., Vroom T.M., Adriaansen-Slot S.S., Ottenhoff-Kalff A.E., Geertzema J.G., Hennipman A., et al. c-Src protein expression is increased in human breast cancer. An immunohistochemical and biochemical analysis. J. Pathol. 180 (1996) 383-388
113. Cas expression in untreated and acquired tamoxifen-resistant human breast carcinomas. Int. J. Cancer 89 (2000) 465-468
114. Biscardi J.S., Belsches A.P., and Parsons S.J. Characterization of human epidermal growth factor receptor and c-Src interactions in human breast tumor cells. Mol. Carcinog. 21 (1998) 261-272
115. Belsches-Jablonski A.P., Biscardi J.S., Peavy D.R., Tice D.A., Romney D.A., and Parsons S.J. Src family kinases and HER2 interactions in human breast cancer cell growth and survival. Oncogene 20 (2001) 1465-1475
116. Gotoh T., Cai D., Tian X., Feig L.A., and Lerner A. p130cas regulates the activity of AND-34, a novel Ral, Rap1, and R-Ras guanine nucleotide exchange factor. J. Biol. Chem. 275 (2000) 30118-30123
117. Cai D., Felekkis K.N., Near R.I., O'Neill G.M., van Seventer J.M., Golemis E.A., et al. The GDP exchange factor AND-34 is expressed in B cells, associates with HEF1, and activates Cdc42. J. Immunol. 170 (2003) 969-978
118. Felekkis K.N., Narsimhan R.P., Near R., Castro A.F., Zheng Y., Quilliam L.A., et al. AND-34 activates phosphatidylinositol 3-kinase and induces anti-estrogen resistance in a SH2 and GDP exchange factor-like domain-dependent manner. Mol. Cancer Res. 3 (2005) 32-41
119. Felekkis K., Quilliam L.A., and Lerner A. Characterization of AND-34 function and signaling. Methods Enzymol. 407 (2005) 55-63
120. Yu Y., and Feig L.A. Involvement of R-Ras and Ral GTPases in estrogen-independent proliferation of breast cancer cells. Oncogene 21 (2002) 7557-7568
121. Toker A., and Yoeli-Lerner M. AKT signaling and cancer: surviving but not moving on. Cancer Res. 66 (2006) 3963-3966
122. Kim D., and Chung J. AKT: versatile mediator of cell survival and beyond. J. Biochem. Mol. Biol. 35 (2002) 106-115
123. Campbell R.A., Bhat-Nakshatri P., Patel N.M., Constantinidou D., Ali S., and Nakshatri H. Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. J. Biol. Chem. 276 (2001) 9817-9824
124. Duong B.N., Elliott S., Frigo D.E., Melnik L.I., Vanhoy L., Tomchuck S., et al. AKT regulation of estrogen receptor β transcriptional activity in breast cancer. Cancer Res. 66 (2006) 8373-8381
125. Faridi J., Wang L., Endemann G., and Roth R.A. Expression of constitutively active AKT-3 in MCF-7 breast cancer cells reverses the estrogen and tamoxifen responsivity of these cells in vivo. Clin. Cancer Res. 9 (2003) 2933-2939
126. DeGraffenried L.A., Friedrichs W.E., Fulcher L., Fernandes G., Silva J.M., Peralba J.M., et al. Eicosapentaenoic acid restores tamoxifen sensitivity in breast cancer cells with high AKT activity. Ann. Oncol. 14 (2003) 1051-1056
127. Clark A.S., West K., Streicher S., and Dennis P.A. Constitutive and inducible AKT activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol. Cancer Ther. 1 (2002) 707-717
128. Jordan N.J., Gee J.M., Barrow D., Wakeling A.E., and Nicholson R.I. Increased constitutive activity of PKB/AKT in tamoxifen resistant breast cancer MCF-7 cells. Breast Cancer Res. Treat. 87 (2004) 167-180
129. Frogne T., Jepsen J.S., Larsen S.S., Fog C.K., Brockdorff B.L., and Lykkesfeldt A.E. Antiestrogen-resistant human breast cancer cells require activated protein kinase B/AKT for growth. Endocr. Relat. Cancer 12 (2005) 599-614
130. Brodie A., Sabnis G., and Jelovac D. Aromatase and breast cancer. J. Steroid Biochem. Mol. Biol. 102 (2006) 97-102
131. Mamane Y., Petroulakis E., LeBacquer O., and Sonenberg N. mTOR, translation initiation and cancer. Oncogene 25 (2006) 6416-6422
132. DeGraffenried L.A., Friedrichs W.E., Russell D.H., Donzis E.J., Middleton A.K., Silva J.M., et al. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant AKT activity. Clin. Cancer Res. 10 (2004) 8059-8067
133. Boulay A., Rudloff J., Ye J., Zumstein-Mecker S., O'Reilly T., Evans D.B., et al. Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer. Clin. Cancer. Res. 11 (2005) 5319-5328
134. Carraway H., and Hidalgo M. New targets for therapy in breast cancer: mammalian target of rapamycin (mTOR) antagonists. Breast Cancer Res. 6 (2004) 219-224
135. Johnston S.R. Targeting downstream effectors of epidermal growth factor receptor/HER2 in breast cancer with either farnesyltransferase inhibitors or mTOR antagonists. Int. J. Gynecol. Cancer 16 Suppl. 2 (2006) 543-548
136. Lannigan D.A. Estrogen receptor phosphorylation. Steroids 68 (2003) 1-9
137. Murphy L.C., Weitsman G.E., Skliris G.P., Teh E.M., Li L., Peng B., et al. Potential role of estrogen receptor alpha (ER alpha) phosphorylated at serine(118) in human breast cancer in vivo. J. Steroid Biochem. Mol. Biol. 102 (2006) 139-146
138. Arnold S.F., Obourn J.D., Jaffe H., and Notides A.C. Phosphorylation of the human estrogen receptor on tyrosine 537 in vivo and by Src family tyrosine kinases in vitro. Mol. Endocrinol. 9 (1995) 24-33
139. Yudt M.R., Vorojeikina D., Zhong L., Skafar D.F., Sasson S., Gasiewicz T.A., et al. Function of estrogen receptor tyrosine 537 in hormone binding, DNA binding, and transactivation. Biochemistry 38 (1999) 14146-14156
140. Weis K.E., Ekena K., Thomas J.A., Lazennec G., and Katzenellenbogen B.S. Constitutively active human estrogen receptors containing amino acid substitutions for tyrosine 537 in the receptor protein. Mol. Endocrinol. 10 (1996) 1388-1398
141. Tremblay G.B., Tremblay A., Labrie F., and Giguere V. Ligand-independent activation of the estrogen receptors alpha and beta by mutations of a conserved tyrosine can be abolished by antiestrogens. Cancer Res. 58 (1998) 877-881
142. Rogatsky I., Trowbridge J.M., and Garabedian M.J. Potentiation of human estrogen receptor alpha transcriptional activation through phosphorylation of serines 104 and 106 by the cyclin A-CDK2 complex. J. Biol. Chem. 274 (1999) 22296-22302
143. Michalides R., van Tinteren H., Balkenende A., Vermorken J.B., Benraadt J., Huldij J., et al. Cyclin A is a prognostic indicator in early stage breast cancer with and without tamoxifen treatment. Br. J. Cancer 86 (2002) 402-408
144. Arnold S.F., Obourn J.D., Jaffe H., and Notides A.C. Serine 167 is the major estradiol-induced phosphorylation site on the human estrogen receptor. Mol. Endocrinol. 8 (1994) 1208-1214
145. Glaros S., Atanaskova N., Zhao C., Skafar D.F., and Reddy K.B. Activation function-1 domain of estrogen receptor regulates the agonistic and antagonistic actions of tamoxifen. Mol. Endocrinol. 20 (2006) 996-1008
146. Likhite V.S., Stossi F., Kim K., Katzenellenbogen B.S., and Katzenellenbogen J.A. Kinase-specific phosphorylation of the estrogen receptor changes receptor interactions with ligand, deoxyribonucleic acid, and coregulators associated with alterations in estrogen and tamoxifen activity. Mol. Endocrinol. 20 (2006) 3120-3132
147. Chen D., Pace P.E., Coombes R.C., and Ali S. Phosphorylation of human estrogen receptor alpha by protein kinase A regulates dimerization. Mol. Cell. Biol. 19 (1999) 1002-1015
148. Wang R.A., Mazumdar A., Vadlamudi R.K., and Kumar R. p21-activated kinase-1 phosphorylates and transactivates estrogen receptor-alpha and promotes hyperplasia in mammary epithelium. EMBO J. 21 (2002) 5437-5447
149. Balasenthil S., Barnes C.J., Rayala S.K., and Kumar R. Estrogen receptor activation at serine 305 is sufficient to upregulate cyclin D1 in breast cancer cells. FEBS Lett. 567 (2004) 243-247
150. Rayala S.K., Molli P.R., and Kumar R. Nuclear p21-activated kinase 1 in breast cancer packs off tamoxifen sensitivity. Cancer Res. 66 (2006) 5985-5988
151. Rayala S.K., Talukder A.H., Balasenthil S., Tharakan R., Barnes C.J., Wang R.A., et al. p21-activated kinase 1 regulation of estrogen receptor-alpha activation involves serine 305 activation linked with serine 118 phosphorylation. Cancer Res. 66 (2006) 1694-1701
152. Michalides R., Griekspoor A., Balkenende A., Verwoerd D., Janssen L., Jalink K., et al. Tamoxifen resistance by a conformational arrest of the estrogen receptor alpha after PKA activation in breast cancer. Cancer Cell 5 (2004) 597-605
153. Joel P.B., Traish A.M., and Lannigan D.A. Estradiol-induced phosphorylation of serine 118 in the estrogen receptor is independent of p42/p44 mitogen-activated protein kinase. J. Biol. Chem. 273 (1998) 13317-13323
154. Chen D., Riedl T., Washbrook E., Pace P.E., Coombes R.C., Egly J.M., et al. Activation of estrogen receptor alpha by S118 phosphorylation involves a ligand-dependent interaction with TFIIH and participation of CDK7. Mol. Cell 6 (2000) 127-137
155. Chen D., Washbrook E., Sarwar N., Bates G.J., Pace P.E., Thirunuvakkarasu V., et al. Phosphorylation of human estrogen receptor alpha at serine 118 by two distinct signal transduction pathways revealed by phosphorylation-specific antisera. Oncogene 21 (2002) 4921-4931
156. Medunjanin S., Hermani A., De Servi B., Grisouard J., Rincke G., and Mayer D. Glycogen synthase kinase-3 interacts with and phosphorylates estrogen receptor alpha and is involved in the regulation of receptor activity. J. Biol. Chem. 280 (2005) 33006-33014
157. Britton D.J., Hutcheson I.R., Knowlden J.M., Barrow D., Giles M., McClelland R.A., et al. Bidirectional cross talk between ER alpha and EGFR signalling pathways regulates tamoxifen-resistant growth. Breast Cancer Res. Treat. 96 (2006) 131-146
158. Weitsman G.E., Li L., Skliris G.P., Davie J.R., Ung K., Niu Y., et al. Estrogen receptor-alpha phosphorylated at ser118 is present at the promoters of estrogen-regulated genes and is not altered due to HER-2 overexpression. Cancer Res. 66 (2006) 10162-10170
159. Park K.J., Krishnan V., O'Malley B.W., Yamamoto Y., and Gaynor R.B. Formation of an IKK alpha-dependent transcription complex is required for estrogen receptor-mediated gene activation. Mol. Cell 18 (2005) 71-82
160. Caldon C.E., Daly R.J., Sutherland R.L., and Musgrove E.A. Cell cycle control in breast cancer cells. J. Cell. Biochem. 97 (2006) 261-274
161. Butt A.J., McNeil C.M., Musgrove E.A., and Sutherland R.L. Downstream targets of growth factor and oestrogen signalling and endocrine resistance: the potential roles of c-Myc, cyclin D1 and cyclin E. Endocr. Relat. Cancer 12 Suppl. 1 (2005) S47-S59
162. Sherr C.J., and Roberts J.M. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 13 (1999) 1501-1512
163. Sherr C.J., and Roberts J.M. Living with or without cyclins and cyclin-dependent kinases. Genes Dev. 18 (2004) 2699-2711
164. Hui R., Finney G.L., Carroll J.S., Lee C.S., Musgrove E.A., and Sutherland R.L. Constitutive overexpression of cyclin D1 but not cyclin E confers acute resistance to antiestrogens in T-47D breast cancer cells. Cancer Res. 62 (2002) 6916-6923
165. Kilker R.L., Hartl M.W., Rutherford T.M., and Planas-Silva M.D. Cyclin D1 expression is dependent on estrogen receptor function in tamoxifen-resistant breast cancer cells. J. Steroid Biochem. Mol. Biol. 92 (2004) 63-71
166. O'Regan R.M., Osipo C., Ariazi E., Lee E.S., Meeke K., Morris C., et al. Development and therapeutic options for the treatment of raloxifene-stimulated breast cancer in athymic mice. Clin. Cancer Res. 12 (2006) 2255-2263
167. Kilker R.L., and Planas-Silva M.D. Cyclin D1 is necessary for tamoxifen-induced cell cycle progression in human breast cancer cells. Cancer Res. 66 (2006) 11478-11484
168. Sutherland R.L., and Musgrove E.A. Cyclins and breast cancer. J. Mammary Gland Biol. Neoplasia 9 (2004) 95-104
169. Foster J.S., Henley D.C., Ahamed S., and Wimalasena J. Estrogens and cell-cycle regulation in breast cancer. Trends Endocrinol. Metab. 12 (2001) 320-327
170. Akli S., and Keyomarsi K. Low-molecular-weight cyclin E: the missing link between biology and clinical outcome. Breast Cancer Res. 6 (2004) 188-191
171. Akli S., Zheng P.J., Multani A.S., Wingate H.F., Pathak S., Zhang N., et al. Tumor-specific low molecular weight forms of cyclin E induce genomic instability and resistance to p21, p27, and antiestrogens in breast cancer. Cancer Res. 64 (2004) 3198-3208
172. Dhillon N.K., and Mudryj M. Ectopic expression of cyclin E in estrogen responsive cells abrogates antiestrogen mediated growth arrest. Oncogene 21 (2002) 4626-4634
173. Kip1 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells. Proc. Natl. Acad. Sci. USA 97 (2000) 9042-9046
174. Carroll J.S., Lynch D.K., Swarbrick A., Renoir J.M., Sarcevic B., Daly R.J., et al. p27(Kip1) induces quiescence and growth factor insensitivity in tamoxifen-treated breast cancer cells. Cancer Res. 63 (2003) 4322-4326
175. Liang J., and Slingerland J.M. Multiple roles of the PI3K/PKB (AKT) pathway in cell cycle progression. Cell Cycle 2 (2003) 339-345
176. WAF1/CIP1 expression during estrogen signaling and antiestrogen resistance in human breast cancer cells. J. Biol. Chem. 280 (2005) 17617-17625
177. Donovan J.C., Milic A., and Slingerland J.M. Constitutive MEK/MAPK activation leads to p27(Kip1) deregulation and antiestrogen resistance in human breast cancer cells. J. Biol. Chem. 276 (2001) 40888-40895
178. Dowsett M., Houghton J., Iden C., Salter J., Farndon J., A'Hern R., et al. Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status. Ann. Oncol. 17 (2006) 818-826
179. Hiscox S., Morgan L., Barrow D., Dutkowskil C., Wakeling A., and Nicholson R.I. Tamoxifen resistance in breast cancer cells is accompanied by an enhanced motile and invasive phenotype: Inhibition by gefitinib ('Iressa', ZD1839). Clin. Exp. Metastasis 21 (2004) 201-212
180. Kang Y., and Massague J. Epithelial-mesenchymal transitions: twist in development and metastasis. Cell 118 (2004) 277-279
181. Hiscox S., Morgan L., Green T.P., Barrow D., Gee J., and Nicholson R.I. Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells. Breast Cancer Res. Treat. 97 (2006) 263-274
182. Lee J.M., Dedhar S., Kalluri R., and Thompson E.W. The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J. Cell Biol. 172 (2006) 973-981
183. Schraml P., Schwerdtfeger G., Burkhalter F., Raggi A., Schmidt D., Ruffalo T., et al. Combined array comparative genomic hybridization and tissue microarray analysis suggest Pak1 at 11q13.5-q14 as a critical oncogene target in ovarian carcinoma. Am. J. Pathol. 163 (2003) 985-992
184. Robanus-Maandag E.C., Bosch C.A., Kristel P.M., Hart A.A., Faneyte I.F., Nederlof P.M., et al. Association of c-Myc amplification with progression from the in situ to the invasive stage in c-Myc-amplified breast carcinomas. J. Pathol. 201 (2003) 75-82
185. Tokunaga E., Kimura Y., Mashino K., Oki E., Kataoka A., Ohno S., et al. Activation of PI3K/AKT signaling and hormone resistance in breast cancer. Breast Cancer 13 (2006) 137-144
186. Shoman N., Klassen S., McFadden A., Bickis M.G., Torlakovic E., and Chibbar R. Reduced PTEN expression predicts relapse in patients with breast carcinoma treated by tamoxifen. Mod. Pathol. 18 (2005) 250-259
187. Kenny F.S., Hui R., Musgrove E.A., Gee J.M., Blamey R.W., Nicholson R.I., et al. Overexpression of cyclin D1 messenger RNA predicts for poor prognosis in estrogen receptor-positive breast cancer. Clin. Cancer Res. 5 (1999) 2069-2076
188. Stendahl M., Kronblad A., Ryden L., Emdin S., Bengtsson N.O., and Landberg G. Cyclin D1 overexpression is a negative predictive factor for tamoxifen response in postmenopausal breast cancer patients. Br. J. Cancer 90 (2004) 1942-1948
189. Span P.N., Tjan-Heijnen V.C., Manders P., Beex L.V., and Sweep C.G. Cyclin-E is a strong predictor of endocrine therapy failure in human breast cancer. Oncogene 22 (2003) 4898-4904
190. Desmedt C., Ouriaghli F.E., Durbecq V., Soree A., Colozza M.A., Azambuja E., et al. Impact of cyclins E, neutrophil elastase and proteinase 3 expression levels on clinical outcome in primary breast cancer patients. Int. J. Cancer 119 (2006) 2539-2545
191. Kip1 expression predicts superior relapse-free and overall survival for premenopausal women with early-stage breast cancer receiving adjuvant treatment with tamoxifen plus goserelin. J. Clin. Oncol. 21 (2003) 3594-3600
192. WAF1/CIP1 correlates with AKT activation and poor response to tamoxifen in breast cancer. Int. J. Oncol. 28 (2006) 1031-1042
193. Murphy L.C., Niu Y., Snell L., and Watson P. Phospho-serine-118 estrogen receptor-alpha expression is associated with better disease outcome in women treated with tamoxifen. Clin. Cancer Res. 10 (2004) 5902-5906
194. Bergqvist J., Elmberger G., Ohd J., Linderholm B., Bjohle J., Hellborg H., et al. Activated ERK1/2 and phosphorylated oestrogen receptor alpha are associated with improved breast cancer survival in women treated with tamoxifen. Eur. J. Cancer 42 (2006) 1104-1112
195. Yamashita H., Nishio M., Kobayashi S., Ando Y., Sugiura H., Zhang Z., et al. Phosphorylation of estrogen receptor alpha serine 167 is predictive of response to endocrine therapy and increases postrelapse survival in metastatic breast cancer. Breast Cancer Res. 7 (2005) R753-R764
196. Bardou V.J., Arpino G., Elledge R.M., Osborne C.K., and Clark G.M. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J. Clin. Oncol. 21 (2003) 1973-1979
197. Ferno M., Stal O., Baldetorp B., Hatschek T., Kallstrom A.C., Malmstrom P., et al. Results of two or five years of adjuvant tamoxifen correlated to steroid receptor and S-phase levels. South Sweden Breast Cancer Group, and South-East Sweden Breast Cancer Group. Breast Cancer Res. Treat. 59 (2000) 69-76
198. Ellis M.J., Coop A., Singh B., Tao Y., Llombart-Cussac A., Janicke F., et al. Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status. Cancer Res. 63 (2003) 6523-6531
199. Jansen M.P., Foekens J.A., van Staveren I.L., Dirkzwager-Kiel M.M., Ritstier K., Look M.P., et al. Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling. J. Clin. Oncol. 23 (2005) 732-740
200. Goetz M.P., Suman V.J., Ingle J.N., Nibbe A.M., Visscher D.W., Reynolds C.A., et al. A two-gene expression ratio of homeobox 13 and interleukin-17B receptor for prediction of recurrence and survival in women receiving adjuvant tamoxifen. Clin. Cancer Res. 12 (2006) 2080-2087
201. Reid J.F., Lusa L., De Cecco L., Coradini D., Veneroni S., Daidone M.G., et al. Limits of predictive models using microarray data for breast cancer clinical treatment outcome. J. Natl. Cancer Inst. 97 (2005) 927-930
202. Frasor J., Stossi F., Danes J.M., Komm B., Lyttle C.R., and Katzenellenbogen B.S. Selective estrogen receptor modulators: discrimination of agonistic versus antagonistic activities by gene expression profiling in breast cancer cells. Cancer Res. 64 (2004) 1522-1533
203. Hur J., Chesnes J., Coser K.R., Lee R.S., Geck P., Isselbacher K.J., et al. The Bik BH3-only protein is induced in estrogen-starved and antiestrogen-exposed breast cancer cells and provokes apoptosis. Proc. Natl. Acad. Sci. USA 101 (2004) 2351-2356
204. Itoh T., Karlsberg K., Kijima I., Yuan Y.C., Smith D., Ye J., et al. Letrozole-, anastrozole- and tamoxifen-responsive genes in MCF-7aro cells: a microarray approach. Mol. Cancer Res. 3 (2005) 203-218
205. Becker M., Sommer A., Kratzschmar J.R., Seidel H., Pohlenz H.D., and Fichtner I. Distinct gene expression patterns in a tamoxifen-sensitive human mammary carcinoma xenograft and its tamoxifen-resistant subline MaCa 3366/TAM. Mol. Cancer Ther. 4 (2005) 151-168
206. Bowie M.L., Dietze E.C., Delrow J., Bean G.R., Troch M.M., Marjoram R.J., et al. Interferon-regulatory factor-1 is critical for tamoxifen-mediated apoptosis in human mammary epithelial cells. Oncogene 23 (2004) 8743-8755
207. Xu K., and Geczy C.L. IFN-gamma and TNF regulate macrophage expression of the chemotactic S100 protein S100A8. J. Immunol. 164 (2000) 4916-4923
208. Jeffrey S.S., Lonning P.E., and Hillner B.E. Genomics-based prognosis and therapeutic prediction in breast cancer. J. Natl. Compr. Canc. Netw. 3 (2005) 291-300
209. Fan C., Oh D.S., Wessels L., Weigelt B., Nuyten D.S., Nobel A.B., et al. Concordance among gene-expression-based predictors for breast cancer. N. Engl. J. Med. 355 (2006) 560-569
210. Paik S. Methods for gene expression profiling in clinical trials of adjuvant breast cancer therapy. Clin. Cancer Res. 12 (2006) 1019S-1023S
211. Dowsett M., Nicholson R.I., and Pietras R.J. Biological characteristics of the pure antiestrogen fulvestrant: overcoming endocrine resistance. Breast Cancer Res. Treat. 93 Suppl. 1 (2005) S11-S18
212. Johnston S.R. Clinical efforts to combine endocrine agents with targeted therapies against epidermal growth factor receptor/human epidermal growth factor receptor 2 and mammalian target of rapamycin in breast cancer. Clin. Cancer Res. 12 (2006) 1061S-1068S
213. Head J., and Johnston S.R. New targets for therapy in breast cancer: farnesyltransferase inhibitors. Breast Cancer Res. 6 (2004) 262-268
214. Leary A., and Dowsett M. Combination therapy with aromatase inhibitors: the next era of breast cancer treatment?. Br. J. Cancer 95 (2006) 661-666
215. Chan S., Scheulen M.E., Johnston S., Mross K., Cardoso F., Dittrich C., et al. Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J. Clin. Oncol. 23 (2005) 5314-5322
216. Perey L., Paridaens R., Hawle H., Zaman K., Nole F., Wildiers H., et al. Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00). Ann. Oncol. 18 (2007) 64-69